News
Caladrius Biosciences Announces First Patient Dosed in Phase 3 Immunotherapy Trial for Melanoma
Bioprocess InsiderCaladrius Biosciences Announces First Patient Dosed in Phase 3 Immunotherapy Trial for MelanomaCaladrius Biosciences Announces First Patient Dosed in Phase 3 Immunotherapy Trial for Melanoma
Caladrius Biosciences, Inc., has dosed the first patient in a melanoma clinical trial with Intus, a targeted cancer immunotherapy (CLBS20)
Goodwin Biotechnology and Aspyrian Therapeutics Collaborate on the Successful GMP Manufacturing and IND Submission for a Novel Antibody Drug
Bioprocess InsiderGoodwin Biotechnology and Aspyrian Therapeutics Collaborate on the Successful GMP Manufacturing and IND Submission for a Novel Antibody Drug Conjugate (ADC) PlatformGoodwin Biotechnology and Aspyrian Therapeutics Collaborate on the Successful GMP Manufacturing and IND Submission for a Novel Antibody Drug Conjugate (ADC) Platform